Cellular internalization and mechanism of cytotoxicity of 131 I-Rituximab in raji cells

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 32, Issue 2, 2013, Pages 91-99

  Kumar, Chandan ^a   Pandey, B N ^a   Samuel, Grace ^a   Venkatesh, Meera ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

131I rituximab; Apoptosis; Cellular internalization; Lymphoma; Rituximab; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; LACTATE DEHYDROGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P53; RADIOPHARMACEUTICAL AGENT; RITUXIMAB I 131; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CULTURE MEDIUM; CYTOPLASM; CYTOTOXICITY TEST; DEIODINATION; DNA FRAGMENTATION; DRUG BINDING; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PURIFICATION; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INTERNALIZATION; MOLECULAR MECHANICS; PAPER ELECTROPHORESIS; PRIORITY JOURNAL; RADIOACTIVITY; RAJI CELL; SUPERNATANT; TIME; TUMOR CELL; UPREGULATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MEMBRANE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOPLASM; DNA DAMAGE; HUMANS; LYMPHOMA, B-CELL; POLY(ADP-RIBOSE) POLYMERASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84884128802     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvironPatholToxicolOncol.2013006843     Document Type: Article

References (23)

1. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti CD20 monoclonal antibody rituximab. Ann Oncol. 2003;14:520-535.
2. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Rabb R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chime-ric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-445.
3. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus, GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leu-kemias and lymphomas: a model of human B cell differentiation. Blood. 1984:63:1424-1433.
4. Multani PS, Grossbard ML. Monoclonal antibody-based therapies for hematologic malignancies. J Clin Oncol. 1998;16:3691-3710.
5. Kunala S, Macklis RM. Ionizing radiation induces CD20 expression on human B cells. Int J Cancer. 2001;96:178-181.
6. Ehrlich P. The collected papers of Paul Ehrlich. Vol. 3. London: Pergamon; 1960.
7. Pohlman B, Sweetenham J, Macklis RM. Review of clinical radioimmunotherapy. Expert Rev Anti-cancer Ther. 2006;6:445-461.
8. Mach JP, Carrel S, Merenda C, Sordat B, Cerot-tini JC. In vivo localisation of radiolabelled antibodies to carcinoembryonic antigen in human colon carcinoma grafted into nude mice. Nature. 1974;248:704-706.
9. Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov. 2004;3:488-499.
10. Govindan SV, Griffths GL, Hansen HJ, Horak ID, Goldenberg DM. Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies. Technol Cancer Res Treat. 2005;4:375-391.
11. Britz-Cunningham SH, Adelstein SJ. Molecular targeting with radionuclides: state of science. J Nucl Med. 2003;44:1945-1961.
12. Chinol M, Vallabhajosula S, Goldsmith SJ, Klein MJ, Deutsch KF, Chinen LK, Brodack JW, Deutsch EA, Watson BA, Tofe AJ. Chemistry and biological behavior of samarium-153 and rhenium-186-la-beled hydroxyapatite particles: potential radio-pharmaceuticals for radiation synovectomy. J Nucl Med. 1993;34:1536-1542.
13. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005;6:392-400.
14. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled so-matostatin-analogue for cancer treatment. Lancet. 1998;351:417-418.
15. Boelaert K, Franklyn JA. Sodium iodide symport-er: a novel strategy to target breast, prostrate and other cancers? Lancet. 2003;361:796-797.
16. Sharkey RM, Burton J, Goldenberg DM. Radio-immunotherapy of non-Hodgkin's lymphoma: a critical appraisal. Expert Rev Clin Immunol. 2005;1:47-62.
17. Tran L, Baars JW, de Boer JP, Hoefnagel CA, Bei-jnen JH, Huitema AD. The pharmacokinetics of 131I-rituximab in a patient with CD20 positive non-Hodgkin lymphoma: evaluation of the effect of ra-dioiodination on the biological properties of ritux-imab. Hum Antibodies. 2011;20:37-40.
18. 131I-Rituximab against B-cell lym-phoma cells. Nan Fang Yi Ke Da Xue Xue Bao. 2009;29:40-43.
19. 131I-rituximab. Nan Fang Yi Ke Da Xue Xue Bao. 2006;26:211-213.
20. Fraker P. Speck J. Protein and cell membrane iodin-ations with a sparingly soluble chloroamide,1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun. 1978;80:849-857.
21. Goddu SM, Rao DV, Howell RW. Multicellular do-simetry for micrometastases: dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides. J Nucl Med. 1994;35:521-530.
22. Shih LB, Thorpe SR, Griffths GL, Diril H, Ong GL, Hansen HJ, Goldenberg DM, Mattes MJ. The processing and fate of antibodies and their radio-labels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med. 1994;35:899-908.
23. Bonavida B. Rituximab-induced inhibition of an-tiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsive-ness, prognostic and novel therapeutic interventions. Oncogene. 2007;26:3629-3636.